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Abstract: Dietary methyl donors, including folate, may modify the placenta and size at birth but the
influence of maternal body weight has not been widely investigated. We therefore examined whether
maternal or fetal folate status, together with indices of placental folate transport, were modulated
by either maternal pre-pregnancy body mass index (BMI i.e., overweight: 25 ≤ BMI < 30 or obesity:
BMI≥ 30 kg/m2) and/or gestational diabetes mellitus (GD). We utilised a sub-sample of 135 pregnant
women participating in the Spanish PREOBE survey for our analysis (i.e., 59 healthy normal weight,
29 overweight, 22 obese and 25 GD). They were blood sampled at 34 weeks gestation, and, at delivery,
when a placental sample was taken together with maternal and cord blood. Placental gene expression
of folate transporters and DNA methyltransferases (DNMT) were all measured. Folate plasma
concentrations were determined with an electro-chemiluminescence immunoassay. Food diaries
indicated that folate intake was unaffected by BMI or GD and, although all women maintained
normal folate concentrations (i.e., 5–16 ng/mL), higher BMIs were associated with reduced maternal
folate concentrations at delivery. Umbilical cord folate was not different, reflecting an increased
concentration gradient between the mother and her fetus. Placental mRNA abundance for the folate
receptor alpha (FOLR1) was reduced with obesity, whilst DNMT1 was increased with raised BMI,
responses that were unaffected by GD. Multi-regression analysis to determine the best predictors
for placental FOLR1 indicated that pre-gestational BMI had the greatest influence. In conclusion,
the placenta’s capacity to maintain fetal folate supply was not compromised by either obesity or GD.
Keywords: body mass index; gestational diabetes; placenta; folic acid
1. Introduction
Folate is an essential cofactor in metabolic pathways that influence DNA methylation patterns,
DNA synthesis and cell proliferation [1,2]. It is crucial to the 1-carbon cycle where it acts as a transporter
of CH3 and the single carbon donor in one carbon metabolism [3]. Limited dietary availability can
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contribute to abnormal DNA methylation patterns in mice [4] and, thus, potentially to developmental
programming [5]. Fortification of the diet with folic acid has been adopted by many countries to
ensure that dietary intake is rarely limited, particularly during pregnancy, in order to prevent neural
tube defects when folate requirements can increase because of increased rates of cell division and
growth, especially during embryo development [6,7]. Indeed, it is now recommended that, during
pregnancy, there should be no upper limit on dietary intake [8]. Pregnant women with high body mass
index (BMI) and gestational diabetes (GD) can have inadequate dietary intakes of folate [9–11] and
lower folate concentrations [12,13]. This could contribute to some of the adverse neonatal outcomes
associated with maternal obesity [14], including greater risks of preterm deliveries, neural tube defects
and low birth weight [15–17].
Cellular uptake of folate is mediated by specific transport mechanisms in the placenta,
which include the folate receptor alpha (FOLR1), proton coupled folate transporter (PCFT), and folate
carrier (RFC) [18,19]. Of these mechanisms, FOLR1 appears to be the most important, at least as
far as preterm births are concerned [20]. Folate is bound to the FOLR1 on the maternal side of the
placenta and then transported to the fetal circulation by endocytosis/exocytosis [21]. The impact of
maternal obesity on the potential capacity of the placenta to modulate folate status acting through
FOLR1 has not been examined extensively in humans. One study in women in Texas found that when
gestational weight gain was similar in obese and non-obese women, fetal serum folate concentrations
and placental folate transport activity were unaffected [22].
The present study, was designed to explore the effects of a raised maternal pre-pregnancy
BMI and/or gestational diabetes on markers of folate placental transport and metabolism, taking
into account folic acid status and intake under these different maternal metabolic environments.
We hypothesised that as folate has a crucial role in providing methyl donors [3], it can influence
gene expression for DNA methyltransferases (DNMT1) and DNMT3A [4]. We therefore examined
whether potential changes in placental folate transport resulting from high maternal BMI and/or
GD, would modulate gene expression of DNMT. Our study was conducted in pregnant women from
Spain recruited as part of the PREOBE study in which we have previously shown that placental
expression of genes involved in energy sensing and oxidative stress are sensitive to maternal obesity
(i.e., BMI ≥ 30 kg/m2) and GD [23].
2. Materials and Methods
2.1. Participants
The participants were part of a longitudinal study on the influence of body composition by
maternal genetics and nutrition (PREOBE Excellence Project: P06-CTS-02341) undertaken between
2007 and 2010 and registered with www.ClinicalTrials.gov, (NCT01634464) [24–26] for which full
details have already been published (and are summarised in Table 1 [23]). It was conducted according
to the guidelines in the Declaration of Helsinki and all experimental procedures were approved by
the Ethics Committees for Granada University, San Cecilio University Hospital and the University
of Nottingham. Witnessed, written informed consent was obtained from all participants before their
study inclusion and they were assured of anonymity. Anthropometric assessments of mothers and
newborns were undertaken following the standards established by the Spanish Society of Gynaecology
and Obstetrics, the Fetal Foundation and the Spanish Association of Paediatrics. Gestational Diabetes
was diagnosed according to the Spanish consensus protocol established by the Grupo Español de
Diabetes y Embarazo (GEDE) of the Gynecology and Obstetricians Society, followed by Andalusian
pregnant women general practitioners [27]. The O’Sullivan test was performed on all pregnant women
between 24–28 weeks of pregnancy, as screening for gestational diabetes. If glucose was ≥140 mg/dL
an oral glucose tolerance test (OGTT) with 100 g of glucose loading was performed. Gestational
diabetes was diagnosed if two or more glucose values met or exceeded the following values fasting
<105 mg/dL, one hour <190 mg/dL, two hours <165 mg/dL, three hours <145 mg/dL. Women with
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plasma glucose ≥200 mg/dL after O’Sullivan test were diagnosed of gestational diabetes and OGTT
was not performed. The O’Sullivan screening test was also performed in the first trimester in high risk
pregnant women (maternal age >35 years; BMI > 30 kg/m2, previous gestational diabetes or other
glucose metabolic alterations, previous obstetric results with an indication of undiagnosed gestational
diabetes (e.g., foetal macrosomy), family history of diabetes mellitus, ethnic risk groups (Afroamericans,
Asiatic-Americans, Hispanic, Indio-Americans))
Table 1. Summary of maternal age, body and birth weights of all participants.
N (n = 59) OW (n = 29) O (n = 22) GDN (n = 14) GDO (n = 11)
Maternal characteristics
Age at delivery (years) 30.4 ± 4.5 30.9 ± 7.2 29.0 ± 4.7 33.1 ± 4.1 * 34.7 ± 4.3 **
Height (cm) 162.9 ± 5.7 162.5 ± 6.4 162.7 ± 6.2 159.3 ± 3.9 160.5 ± 6.0
Pre pregnancy BMI (kg/m2) 21.8 ± 1.8 27.8 ± 2.2 *** 32.5 ± 2.6 *** 22.4 ± 1.8 35.5 ± 4.9 ***
BMI at 34 weeks (kg/m2) 26.6 ± 2.6 31.3 ± 2.4 *** 35.4 ± 2.4 *** 25.9 ± 2.6 36.4 ± 4.1 ***
GWG 0–34 weeks (kg) 12.6 ± 4.3 9.9 ± 4.6 ** 7.3 ± 5.1 *** 9.0 ± 5.6 ** 2.2 ± 7.8 ***
Preterm (<37 gestational weeks) (n) 2 (3%) 1 (3%) 2 (9%). 1 (14%) 4 (27%) *
Male newborn (%) 53 40 62 57 73
Number of caesarean section (%) 12 26 38 25 50
Number on supplements + 45 26 22 12 9
Infant characteristics
Newborn weight (g) 3292 ± 410 3230 ± 587 3454 ± 549 3374 ± 402 3415 ± 549
Placental weight (g) 469 ± 120 495 ± 135 531 ± 114 * 498 ± 134 476 ± 93
Placental: birth weight ratio 0.14 ± 0.03 0.16 ± 0.05 0.16 ± 0.04 0.15 ± 0.04 0.14 ± 0.02
Gestational age (weeks) 39.2 ± 1.0 39.4 ± 1.6 39.3 ± 1.7 39.3 ± 1.3 38.8 ± 1.3
Pre: pregestational; BMI: body mass index; GWG: gestational weight gain during the first 34 gestational weeks based
on 2009 IOM guidelines for each category [28]. + reported taking folate and iodine supplements at 24th week of
gestation. Values are means ± SD or categorical data as appropriate; n: number of women per group; gw: weeks of
gestational. Statistical differences: * p < 0.05, ** p < 0.01, *** p < 0.001 compared to normal w eight group (Chi-square
test or t-independent test for continuous variables; chi-square test for categorical variables). Based on their pre-
pregnancy weights they were classified as being of normal weight (N), overweight (OW), obese (O), gestational
diabetic, normal weight (GDN) or gestational diabetic, obese (GDO) pregnant women (Martino et al., 2016) [23].
As shown in Table 1, the subpopulation of 135 participants whose placentas underwent molecular
analysis in Nottingham, for which a majority that gave birth at full term i.e., c. 39 weeks [23],
with the exception of GDO for which 50% underwent caesarean section delivery. The number of
participants per group were, therefore, 59 normal weight women (18≤ pre-pregnancy BMI < 25 kg/m2
(N)), 29 overweight women (25 ≤ BMI < 30 kg/m2 (OW)) and 22 obese women (BMI ≥ 30 kg/m2
(O)). Furthermore, the 25 mothers with GD were subsequently classified according to their BMI as
normal weight GD (pre-pregnancy BMI < 25 kg/m2 (GDN), n = 14) and as obese GD (pre-pregnancy
BMI ≥ 30 kg/m2 (GDO), n = 11). There were no effects of the sex of the baby, route of delivery or
gestational age on any of the measurements reported in this study.
2.2. Maternal Nutrient Intake
Information about maternal nutrient intake was collected during late gestation (34–40 weeks)
using standardised 7 day dietary records given to the participants during the second visit (34th
gestational week). Each participant was given verbal and written instructions by the investigator on
how to record food and drinks consumed during the 7 day recording period and a booklet of common
food items and mixed dishes to facilitate estimation of portion sizes. Around the time of delivery,
food records were reviewed with each mother by a nutritionist for completeness and accuracy of food
description and portion sizes. Nutritional data were analysed for nutrient intake by using a nutritional
software program (CESNID 1.0: Barcelona University, Spain) based on validated Spanish food tables
(“Tablas de composición de alimentos del CESNID”) [29] and took account of those products fortified with
folic acid.
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2.3. Collection and Analysis of Blood Samples
Maternal venous blood was collected at 34 weeks of gestation and during labour (N: n = 59;
OW: n = 29; O: n = 22; GDN: n = 14; GDO: n = 11). Umbilical venous blood samples (N: n = 33;
OW: n = 15; O: n = 12; GDN: n = 7; GDO: n = 7) were collected within 30 min after placental delivery
from a double-clamped section of umbilical cord. EDTA and serum collection tubes were used
(Vacutainer® Refs: 368857 and 367953) for haematological assessment and biochemical analyses
respectively. There were no differences in any of the measurements performed on the placenta between
those women from whom blood was sampled and those in whom this could not be achieved e.g.,
born at a time when sampling could not be undertaken.
Blood samples for serum preparation were held at 4 ◦C for 15 min to allow blood clotting,
centrifuged at 3500 rpm for 10 min at 4 ◦C, and the serum fraction transferred into sterile tubes.
Samples were stored at 4 ◦C for same-day analyses or at −80 ◦C for further analysis. Serum folate was
determined by an electro-chemiluminescence immunoassay with the automatic analyser Elecsys 2010,
and the analytical kit No. E170 (Roche, Neuilly sur Seine, France).
2.4. Collection of Placenta Samples
Placenta samples from all participants were collected and weighed immediately after delivery as
previously published [23]. Visual inspection of the placenta for necrosis or any other abnormality was
undertaken by experienced clinicians. A representative 0.5× 0.5× 0.5 cm (200 mg) sample was excised
from the middle of the radius (distance between the insertion of the umbilical cord and the periphery)
of each placenta, rinsed twice with saline solution (0.9% NaCl) and immediately placed into sterile
1.5 mL microtubes (Greiner Bio One, Monroe, NC, USA) containing RNAlater solution (Qiagen Ltd.,
Crawley, UK). All samples were frozen under RNase free conditions using liquid nitrogen before
storage at −80 ◦C for later analysis in Nottingham.
2.5. Laboratory Analysis
Total RNA was extracted from 100 mg of maternal placenta tissue using 200 µL of chloroform per
1 mL of TRI reagent solution (Sigma Chemical Co., Poole, UK) and RNeasy extraction kit (Qiagen Ltd.,
Crawley, UK) as previously published [23]. RNA quality was assessed by gel electropheresis. Two µg
RNA was used to generate 20 µL cDNA using High Capacity RNA-to-cDNA kit (Applied Biosystems,
Foster City, CA, USA). Negative control RT samples lacking Enzyme Mix (-RT) were included for
each sample. Real-time PCR using 15 µL of reactions consisting of 4.5 µL diluted 1:10 cDNA, 3.0 µL
(final concentration of 250 nM) gene specific primers (Table 2, Sigma-Aldrich, St. Louis, MO, USA),
and 7.5 µL of SYBR Green mastermix (Thermo Scientific, ABgene Ltd., Epson, UK) were performed.
Duplicate samples were run for 40 cycles with negative controls in 96-well plates using the Techne
Quantica Thermocycler (Techne Inc., Barloword Scientific, Stone, UK). Ten-fold serial dilutions of
cDNA for each gene were used to generate standard curve analysis and only experiments with R2
> 0.985 were included. CT measurements, calculated by 2−∆Ct method [30], were used for mRNA
expression. A range of housekeeping genes were used including ACT8, 18S and B2M, for which 18S
ribosomal RNA was used as the optimal housekeeping gene for data normalisation, as previously
published [23]. It was the most stable housekeeping examined (i.e., N: 0.37 ± 0.08; OW 0.70 ± 0.28;
OB 0.56 ± 0.11; GDL: 0.75 ± 0.14; GDO: 0.13 ± 0.02 a.u.) and the use of other reference genes made no
difference to the results.
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Table 2. Summary of primers used together with qPCR product and conditions.
Target Gene Forward Primer Sequence Reverse Primer Sequence Product Size (bp) Temp (◦C)
FOLR1 CACTCCCTGCCTGTCTCC TCTGCTCTGCTCTACACTCC 80 59
PCFT (SLC46A1) ATGCAGCTTTCTGCTTTGGT GGAGCCACATAGAGCTGGAC 100 60
RFC (SLC19A1) CAGCATCTGGCTGTGCTATG TGATGGTCTTGACGATGGTG 161 59
MTHFR TCCCGTCAGCTTCATGTTCT TGTCGTGGATGTACTGGATGA 116 59
DNMT1 TTCTTCGCAGAGCAAATTGA CGTCATCTGCCTCCTTCATGG 210 57
DNMT3A AAGCCTCAAGAGCAGTGGAA AAGCAGACCTTTAGCCACGA 190 59
FOLR1: folate receptor alpha; PCFT: proton coupled folate transporter; RFC: reduced folate carrier; MTHFR:
methylenetetrahydrofolate reductase; DNMT1: DNA methyl transferase-1; DNMT3A: DNA methyl transferase-3
alpha. bp, base pairs.
2.6. Statistical Analysis
All statistical evaluations were performed by using IBM SPSS v20.0 statistical software for
Windows (IBM Corp., Armonk, NY, USA). To assess the data for normality, a Kolmogorov–Smirnov
test was performed, where p values >0.05 indicated that the data were normally distributed. Thereafter,
appropriate parametric, or non-parametric, tests were used to analyse the effects of maternal
overweight and obesity as follows: (1) comparisons of blood folate concentration at each sampling
age between comparable groups (i.e., N vs. OW, or O, or GDN; GDN vs. GDO) were made by
independent t-test; whilst (2) differences in gene expression were determined by using Mann-Whitney
test. Categorical data were analysed using Chi-square test of independence. Continuous data
(i.e., gene expression and folate concentrations) presented are expressed as means with their standard
errors (SEM), with p values < 0.05 deemed to represent statistical significance. For all analyses
undertaken, there was no effect of foetal sex or route of delivery.
Association between continuous variables were also assessed using multiple linear regression
analysis. It included the following three models: The first was adjusted for the a priori confounder of
pre-gestational BMI; the second, for both BMI and maternal glucose at 34 weeks of gestation and the
third for BMI, maternal glucose and folate at 34 weeks gestation.
3. Results
Maternal Folate Status and Adaptations within the Placenta
Amongst those participants for whom placental analysis was undertaken and who reported
daily intakes of folate (400 µg dietary folate equivalents/day) and iodine supplements at 24th
week of pregnancy, there were no differences in folate or vitamin B12 consumption between groups
(Table 3). Folate concentrations in all participants in the present study were within the normal range
(6–20 ng/mL) with no evidence of folate deficiency (defined as <5 ng/mL: Figure 1) [7]. GDN women
exhibited the highest serum folate concentrations at 34 gestational weeks compared to the normal
weight group (Figure 1). This could reflect dietary and related advice given to this sub-group, in which
mean folate and vitamin B12 intakes were also highest (Table 3). There was no significant effect of
taking folate supplements in late gestation on maternal folate concentrations at 40 weeks of gestation.
A marked decrease in folate concentrations in late pregnancy was observed in both OW and O
women (Figure 1). Cord blood folate concentrations were not different between groups, reflecting
an increased difference between maternal folate at 40 gestational weeks and umbilical cord folate
with raised maternal BMI (i.e., ∆ folate–N: 5.80 ± 0.81; OW: 7.66 ± 0.82; O: 9.01 ± 0.90 ng/mL
(p < 0.05)). There was also a positive correlation between maternal and newborn plasma folate in
the N (r2 = 0.38; p < 0.0001) and GDN (r2 = 0.81; p = 0.015) groups at 34 weeks gestation and in the N
(r2 = 0.19; p = 0.013) and OW (r2 = 0.48; p = 0.006) groups at 40 weeks gestation. No infants exhibited
any spinal or neural abnormalities.
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Table 3. Mean maternal 7 day dietary intake of folate and vitamin B12 between 34–40 weeks
gestation for each group of women whose body weight category was defined according to their
pre pregnancy BMI.
Maternal Intake
(µg DFE/day)
N
(n = 37)
OW
(n = 15)
O
(n = 8)
GDN
(n = 11)
GDO
(n = 6)
Folate 298 ± 12 258 ± 18 260 ± 46 342 ± 33 299 ± 53
Vitamin B12 5.8 ± 0.5 4.7 ± 0.5 5.3 ± 0.9 10.1 ± 4.1 5.3 ± 1.2
DEF, dietary folate equivalents. Normal weight: N; overweight: OW; obese: O, gestational diabetic, normal weight:
GDN and gestational diabetic, obese: GDO. Values are means ± SD.
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expression, indicated that pre-pregnancy B I had the greatest influence (Table 5), suggesting an
effect present in early gestation. ene expression of placental ethylenetetrahydrofolate reductase
( AD(P) ) (MTHFR), the enzyme that catalyses the synthesis of 5-MTHF, did not significantly change
between BMI groups, but was raised in obese women with GD (Table 4). Whilst placental DNMT3A
gene expression was similar between groups, mean mRNA expression of DNMT1 was higher in
overweight and women (Table 4). No significant correlations were found between placental gene
expression and plasma folate.
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Table 4. Effects of maternal body mass index on gene expression markers of folate transport and
metabolism and DNA methylation in placenta of normal weight (N), overweight (OW), obese (O),
gestational diabetic, normal weight (GDN) and gestational diabetic, obese (GDO) pregnant women.
Pathway NCBISequence
Target
Gene
N
(n = 59)
OW
(n = 29)
O
(n = 21)
GDN
(n = 14)
GDO
(n = 11)
Folate transport
and metabolism
NM_016725.2 FOLR1 1.0 ± 0.9 0.8 ± 0.6 0.5 ± 0.3 * 0.6 ± 0.3 0.5 ± 0.3 *
NM_080669.4 PCFT ψ 1.0 ± 0.6 1.0 ± 0.5 1.1 ± 0.6 0.6 ± 0.7 0.8 ± 0.5
NM_006996.2 RFC ψ 1.0 ± 0.8 0.9 ± 0.5 1.0 ± 0.7 0.8 ± 0.5 0.7 ± 0.5
NM_005957 MTHFR 1.0 ± 0.9 1.0 ± 0.9 0.8 ± 0.6 1.0 ± 0.7 1.5 ± 0.7 *
DNA
methylation
NM_001130823 DNMT1 1.0 ± 1.1 1.8 ± 1.1 ** 1.5 ± 1.2 1.8 ± 1.5 0.5 ± 0.5
NM_022552.4 DNMT3A 1.0 ± 0.9 1.1 ± 1.2 0.7 ± 0.5 0.9 ± 0.9 0.6 ± 0.3
Data expressed relative to housekeeping gene (ribosomal 18S RNA), normalised to the control group to give
the fold change. n = women/group. Data are non-parametric and represent mean ± SD Statistical differences:
* p < 0.05, ** p < 0.01 compared to normal weight group (Mann Whitney test). The abundance of genes denoted
by ψ were measured in a representative selection of 20 N women as insufficient mRNA was not available for
all samples. FOLR1: folate receptor alpha; PCFT: proton coupled folate transporter; RFC: reduced folate carrier;
MTHFR: methylenetetrahydrofolate reductase; DNMT1: DNA methyl transferase-1; DNMT3A: DNA methyl
transferase-3 alpha.
Table 5. Association between placental gene expression of folate receptor alpha (FOLR1) and different
predictors in control, overweight and obese pregnant women with or without gestational diabetes
(n = 135).
Linear Regression
Model B (95% CI) SE B β p
Model 1 ψ
Maternal pre-BMI −0.029 (−0.051, −0.007) 0.011 −0.214 0.009
Model 2 ψψ
Maternal pre-BMI −0.032 (−0.054, −0.009) 0.011 −0.230 0.006
Maternal glucose (34 gw) 0.004 (−0.002, 0.01) 0.003 0.107 0.194
Model 3 ψψψ
Maternal pre-BMI −0.033 (−0.056, −0.011) 0.012 −0.241 0.004
Maternal glucose (34 gw) 0.005 (−0.001, 0.01) 0.003 0.131 0.116
Maternal folate (34 gw) −0.019 (−0.043, 0.005) 0.012 0.128 0.124
ψ Adjusted for the a priori confounders pre-pregnancy BMI; ψψ adjusted for the a priori confounders pre-pregnancy
BMI and maternal glucose at 34 weeks of gestation (gw); ψψψ Adjusted for the a priori confounders pre-pregnancy
BMI, maternal glucose at 34 gw and maternal folate at 34 gw. B: unstandardised beta; 95% CI: 95% Confidence
intervals; SE B: Standard error of unstandardised beta; β: standardised beta (β).
4. Discussion
We show that although maternal folate concentrations were reduced with raised maternal
pre-pregnancy BMI near to term, this was not apparent with GD, suggesting that the dietary advice
provided improved folate status irrespective of any placental adaptations, as seen with obesity. In those
women with raised pre-pregnancy BMI, there was no detectable reduction in cord blood folate and
all infants were healthy at term. This suggests appropriate adaptation in folate transfer across the
placenta, that has been suggested to include a downregulation of FOLR1 gene expression in the
placenta with obesity [19]. The results from our study support such a proposal as gene expression
for the other two transporters, PCFT and RFC, were unaffected. Raised mRNA abundance of FOLR1,
if translated to protein, and accompanied with a decline in maternal folate concentration would result
in the maintenance of cord blood folate as we observed at term with obesity. Alternatively mRNA
transcripts of this folate transporter could undergo further functional modifications, that modulate the
placentas capacity to promote folate transport [31] and, hence, protect normal foetal folate status as
seen in women from Texas, USA [22].
The negative association between raised pre-pregnancy BMI and folate status did not appear to be
related to dietary inadequacy in these women unlike those described by others [9–11]. It is possible that
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other adaptations to a high pre-pregnancy BMI, such as hormonal changes in pregnancy and endocrine
modifications, could contribute [6]. It is possible that adaptations within the maternal microbiome
could impact on maternal folate status [32], as has been shown in the rat during late gestation when
manipulating macronutrient intake [33]. Interestingly, obesity with GD resulted in raised placental
MTHFR gene expression that could ultimately inhibit intracellular homocysteine release by promoting
5-MTHF synthesis [34–36]. Enhanced folate catabolism by the placenta would also limit homocysteine
accumulation within the trophoblast, thereby avoiding foetal complications in women with obesity
and/or GD [35,37].
As folate deficiency has been associated with increased placental S-adenosyl-methionine to
S-adenosyl-homocysteine ratio [38,39] and decreased genomic DNA methylation [40–43], reduced
blood folate with obesity could lower the availability of placental SAM, which is used by DNMTs
to methylate DNA [2,44,45]. Changes in gene expression for DNMT1 could be important in this
regard as it transcribes the enzyme required for the maintenance of DNA methylation [46] although
this was not measured in the present study. DNMT1 is also essential for cellular development [46]
and our observation of raised placental gene expression with increased BMI could impact on these
processes even though DNMT3A was unaffected. These divergent responses could reflect their
contrasting roles, with DNMT3A catalysing de novo DNA methylation during early development,
whilst DNMT1 is responsible for the maintenance of DNA methylation throughout all development
stages [4]. The decreased maternal folate with raised pre-pregnancy BMI and higher mRNA abundance
of DNMT1 in the placenta with similar cord blood folate concentrations, could be indicative of a
compensatory response in order to maintain adequate methylation status, for which no differences
were found when measured in five subjects per study group [47]. Overall the relatively small sample
size was utilised in our study, which might benefit from being undertaken in larger groups of women
of different ethnicity. Such a broader study could be combined with a more detailed assessment of
those epigenetic adaptations which remain to be clarified [48].
5. Conclusions
In conclusion, pregnancies in Spanish women with a high BMI and GD are differentially associated
with changes in maternal serum folate in late gestation, which suggests a protective role by the placenta
of the foetus, further supporting the need to ensure optimal dietary folate intake [8].
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